

Références

1. Geberhiwot T, Haddon A, Labib M. HbA1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose. *Ann Clin Biochem.* 2005 May;42(Pt 3):193-5.
2. Available at: <http://www.princeton.edu/~achaney/tmve/wiki100k/docs/Insulin.html>. Accessed April 23, 2013.
3. Available at: http://www.a4m.com/assets/pdf/bookstore/thera6_ch4.pdf?SESSION_MAIN=dap3mjgnb96luhbj8tcklqp75. Accessed April 29, 2013.
4. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, & Fauci AS. (Eds.). (1994). *Harrison's Principles of Internal Medicine* (13th Ed.), McGraw-Hill.
5. Tzima N, Pitsavos C, Panagiotakos DB, et al. Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people; the Attica study. *Lipids Health Dis.* 2007 Sep 19;6:22.
6. Ryan AS. Insulin resistance with aging: effects of diet and exercise. *Sports Med.* 2000 Nov;30(5):327-46.
7. Campos G, Ryder E, Diez-Ewald M, et al. Prevalence of obesity and hyperinsulinemia: its association with serum lipid and lipoprotein concentrations in healthy individuals from Maracaibo, Venezuela. *Invest Clin.* 2003 Mar;44(1):5-19.
8. Mehran AE, Templeman NM, Brigidi GS, et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. *Cell Metab.* 2012 Dec 5;16(6):723-37.
9. Lemay A, Turcot L, Déchêne F, Dodin S, Forest JC. Hyperinsulinemia in nonobese women reporting a moderate weight gain at the beginning of menopause: a useful early measure of susceptibility to insulin resistance. *Menopause.* 2010 Mar;17(2):321-5.
10. Odeleye OE, de Courten M, Pettitt DJ, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. *Diabetes.* 1997 Aug;46(8):1341-5.
11. Coomans CP, Geerling JJ, Guigas B, et al. Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice. *J Lipid Res.* 2011 Sep;52(9):1712-22.
12. Heller RF. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. *Med Hypotheses.* 1994 May;42(5):307-12.
13. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. *N Engl J Med.* 1996 Apr 11;334(15):952-7.
14. Chu N, Spiegelman D, Hotamisligil GS, Rifai N, Stamper M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. *Atherosclerosis.* 2001 Aug;157(2):495-503.

15. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. *Diabetes Metab Res Rev*. 2006 Nov-Dec;22(6):423-36.
16. Eschwège E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. *Diabetes Metab*. 2003 Sep;29(4 Pt 2):6S19-27.
17. Burnol AF, Morzyglod L, Popineau L. Cross-talk between insulin signaling and cell proliferation pathways. *Ann Endocrinol (Paris)*. 2013 Apr 9. [Epub ahead of print]
18. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *Br J Cancer*. 2001 Feb 2;84(3):417-22.
19. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetier P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. *Diabetes Care*. 2001 May;24(5):843-9.
20. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. *Diabetes Care*. 2005 May;28(5):1240-4.
21. Godsland IF, Crook D, Walton C, Wynn V, Oliver MF. Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. *ArteriosclerThromb*. 1992 Sep;12(9):1030-5.
22. Salonen JT, Lakka TA, Lakka HM, Valkonen VP, Everson SA, Kaplan GA. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. *Diabetes*. 1998 Feb;47(2):270-5.
23. Stannard SR, Johnson NA. Insulin resistance and elevated triglyceride in muscle: more important for survival than "thrifty" genes? *J Physiol*. 2004 Feb 1;554(Pt 3):595-607.
24. Mykkänen L, Kuusisto J, Haffner SM, Pyörälä K, Laakso M. Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. *Arterioscler Thromb*. 1994 Apr;14(4):518-26.
25. Karhapää P, Malkki M, Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. *Diabetes*. 1994 Mar;43(3):411-7.
26. Ko GT, Cockram CS, Woo J, Chan JC. Obesity, insulin resistance and isolated low high-density-lipoprotein cholesterol in Chinese subjects. *Diabet Med*. 2001 Aug;18(8):663-6.
27. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. *Am J Cardiol*. 2002 Sep 5; 90(5A):3G-10G.
28. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. *Diabetes*. 1990 Mar;39(3):283-9.
29. Hansen J, Rinnov A, Krogh-Madsen R, et al. Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. *Diabetes Metab Res Rev*. 2013 Apr 6.

30. Despres JP, Pascot A, Lemieux I. Risk factors associated with obesity: a metabolic perspective. *Ann Endocrinol.* 2000 Dec;61 Suppl 6:31-8.
31. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. *J Clin Invest.* 1985 Mar;75(3):809-17.
32. Feuers RJ, Desai VG, Chen FX, Hunter JD, Duffy PH, Oriaku ET. Effects of dietary restriction on insulin resistance in obese mice. *J Am Aging Assoc.* 2000 Apr;23(2):95-101.
33. Hano T, Nishio I. Treatment of hypertension in the patients with obesity. *Nippon Rinsho.* 2001 May;59(5):973-7.
34. Kopf D, Muhlen I, Kroning G, Sendzik I, Huschke B, Lehnert H. Insulin sensitivity and sodium excretion in normotensive offspring and hypertensive patients. *Metabolism.* 2001 Aug;50(8):929-35.
35. Noda M, Matsuo T, Nagano-Tsuge H, et al. Involvement of angiotensin II in progression of renal injury in rats with genetic non- insulin-dependent diabetes mellitus (Wistar fatty rats). *Jpn J Pharmacol.* 2001 Apr;85(4):416-22.
36. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. *Circulation.* 2001 May 8;103(18):2225-9.
37. Katz AS, Goff DC, Feldman SR. Acanthosis nigricans in obese patients: Presentations and implications for prevention of atherosclerotic vascular disease. *Dermatol Online J.* 2000 Sep;6(1):1.
38. Kaaks R. Plasma insulin, IGF-I and breast cancer. *Gynecol Obstet Fertil.* 2001 Mar;29(3):185-91.
39. Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer. *Eur J Intern Med.* 2000 Oct;11(5):245-52.
40. Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. *Nutr Cancer.* 2000 37(1):19-26.
41. Cook DG, Leverenz JB, McMillian PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. *Am J Pathol.* 2003 Jan;162(1):313-9.
42. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. *EurUrol.* 2001 Feb;39(2):151-8.
43. Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. *Atherosclerosis.* 1994 Jun;107(2):239-46.
44. Lear SA, Humphries KH, Kohli S, Frohlich JJ, Birmingham CL, Mancini GB. Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT). *Stroke.* 2007 Sep;38(9):2422-9.
45. Chien KL, Lee YT, Sung FC, Hsu HC, Su TC, Lin RS. Hyperinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: a community-based study. *Clin Chem.* 1999 Jun;45(6 Pt 1):838-46.

46. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. *J Sex Med.* 2005 Jan;2(1):96-103.
47. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet.* 2013 Jan 12;381(9861):153-65.
48. Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity and erectile dysfunction: field overview and research priorities. *J Urol.* 2009 Dec;182(6 Suppl):S45-50.
49. Trussell JC, Legro RS. Erectile dysfunction: does insulin resistance play a part? *Fertil Steril.* 2007 Oct;88(4):771-8.
50. Tamler R. Diabetes, obesity, and erectile dysfunction. *Gen Med.* 2009;6 Suppl 1:4-16.
51. Johnson MS, Figueroa-Colon R, Huang TT, Dwyer JH, Goran MI. Longitudinal changes in body fat in African-American and caucasian children: influence of fasting insulin and insulin sensitivity. *J Clin Endocrinol Metab.* 2001 Jul;86(7):3182-7.
52. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. *Diabetes Care.* 2000 Aug;23(8):1097-102.
53. Ye J. Mechanisms of insulin resistance in obesity. *Front Med.* 2013 Mar;7(1):14-24.
54. van 't Riet E, Alsema M, Nijpels G, Dekker JM. Estimating the individual risk of diabetes: not on the grounds of overweight only. *Ned Tijdschr Geneesk.* 2008 Nov 1;152(44):2385-8.
55. Krishnan S, Rosenberg L, Djoussé L, Cupples LA, Palmer JR. Overall and central obesity and risk of type 2 diabetes in U.S. black women. *Obesity (Silver Spring).* 2007 Jul;15(7):1860-6.
56. Rodin J. Insulin levels, hunger, and food intake: an example of feedback loops in body weight regulation. *Health Psychol.* 1985;4(1):1-24.
57. Reinehr T, de Sousa G, Toschke AM, Andler W. Long-term follow-up of cardiovascular disease risk factors in children after an obesity intervention. *Am J Clin Nutr.* 2006 Sep;84(3):490-6.
58. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA.* 2002 May 8;287(18):2414-23.
59. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. *Diabetes Metab Res Rev.* 2000 Mar-Apr;16(2):125-32.
60. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care.* 1999 Feb;22(2):233-40.
61. Lin HJ, Lee BC, Ho YL, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. *Diabetes Care.* 2009 Sep;32(9):1721-6.

62. Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. *Acta Diabetol.* 2012 Aug;49(4):307-14.
63. Xin Z, Yuan MX, Li HX, et al. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. *PLoS One.* 2012;7(7):e40610.
64. Bash, LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident kidney disease even in the absence of albuminuria and retinopathy: atherosclerosis risk in communities (ARIC) study. *Arch Intern Med.* 2008 Dec 8;168(22):2440-7.
65. Polhill TS, Saad S, Poronnik SSP, Fulcher GR, Pollock CA. Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. *Am J Physiol Renal Physiol.* 2004 Aug;287(2):F268-73.
66. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. *Neurology.* 2003 Jan 14;60(1):108-11.
67. Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. *Arch Neurol.* 2006 Aug;63(8):1075-9.
68. Bell DS. Importance of postprandial glucose control. *South Med J.* 2001 Aug;94(8):804-9.
69. Chien KL, Lee BC, Lin HJ, Hsu HC, Chen MF. Association of fasting and post-prandial hyperglycemia on the risk of cardiovascular and all-cause death among non-diabetic Chinese. *Diabetes Res Clin Pract.* 2009 Feb;83(2):e47-50.
70. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of postprandial hyperglycemia. *Am Heart J.* 2004 May;147(5):803-7.
71. Lebovitz HE. Effect of the postprandial state on nontraditional risk factors. *Am J Cardiol.* 2001 Sep 20;88(6A):20H-5H.
72. Sasso FC, Carbonara O, Nasti R, et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. *JAMA.* 2004 Apr 21;291(15):1858-63.
73. Pirgon O, Bilgin H, Cekmez F, Kurku H, Dündar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic Fatty liver disease. *J Clin Res Pediatr Endocrinol.* 2013 Mar 22;5(1):33-9.
74. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J Gastroenterol.* 2013 Feb 9.
75. Hurjui DM, Niță O, Graur LI, Mihalache L, Popescu DS, Graur M. The central role of the non alcoholic fatty liver disease in metabolic syndrome. *Rev Med Chir Soc Med Nat Iasi.* 2012 Apr-Jun;116(2):425-31.
76. Titov VN, Ivanova KV, Malyshev PP, Kaba SI, Shiriaeva IuK. The unity of pathogenesis of insulin resistance syndrome and non-alcoholic fatty disease of liver. The metabolic disorder of fatty acids and triglycerides. *KlinLab Diagn.* 2012 Nov;(11):3-12.

77. Yang WS, Shu XO, Gao J, et al. Prospective evaluation of type 2 diabetes mellitus on the risk of primary liver cancer in Chinese men and women. *Ann Oncol*. 2013 Feb 13.
78. Hopper MK, Brown GW, Funke KA, Pike Brown LR. Prevalence of hyperinsulinemia associated with body mass index, genetic predisposition, and lifestyle in college freshmen students. *J Am Coll Health*. 2012 60(1):27-36.
79. Available at: <http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm>. Accessed April 25, 2013.
80. Available at: <http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/>. Accessed April 25, 2013.
81. Kutyryna IM, Kriachkova AA, Savel'eva SA. The role of hyperinsulinemia and insulin resistance in development of chronic kidney disease in patients with metabolic syndrome. *Ter Arkh*. 2012 84(6):32-6.
82. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. *J Clin Endocrinol Metab*. 2013 Feb;98(2):668-77.
83. Hirsch HA, Iliopoulos D, Tsihlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res*. 2009 Oct 1;69(19):7507-11.
84. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care*. 2010 Jun;33(6):1304-8.
85. Rizos CV, Elisaf MS. Metformin and cancer. *Eur J Pharmacol*. 2013 Apr 5;705(1-3):96-108.
86. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. *Gynecol Oncol*. 2010 Jan;116(1):92-8.
87. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. *World J Gastroenterol*. 2008 Dec 21;14(47):7192-8.
88. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes Control*. 2009 Nov;20(9):1617-22.
89. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. *Cancer Prev Res (Phila)*. 2010 Sep;3(9):1077-83.
90. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care*. 2009 Sep;32(9):1620-5.
91. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. *Cancer Prev Res (Phila)*. 2010 Sep;3(9):1066-76.

92. Takahara M, Kaneto H, Katakami N, Matsuhisa M, Shimomura I. Effect of metformin on hepatic glucose production in Japanese patients with type 2 diabetes mellitus. *Endocr J*. 2012 Sep 30;59(9):845-7.
93. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. *J Endocrinol*. 2010 Apr;205(1):97-106.
94. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. *Diabetes*. 2000 Dec;49(12):2063-9.
95. Moon RJ. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. *Diabetes Obes Metab*. 2007 Jan;9(1):143-5.
96. Bhansali A, Sridhar S. Insulin sensitizers and serum testosterone in men. *Clin Endocrinol (Oxf)*. 2013 Apr 9.
97. Sir T, Castillo T, Munoz S, Lopez G, Calvillan M. Effects of metformin on insulin resistance in obese and hyperandrogenic women. *Rev Med Chil*. 1997 Dec;125(12):1457-63.
98. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. *Clin Breast Cancer*. 2008 Dec;8(6):501-5.
99. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. *Diabetol Metab Syndr*. 2013 Feb 15;5(1):6.
100. Vaikkakara S, Al-Ozairi E, Lim E, et al. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. *Gynecol Endocrinol*. 2008 Feb;24(2):87-92.
101. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. *Ann Neurol*. 2010 Apr;67(4):534-41.
102. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). *Diabetologia*. 1996 Mar;39(3):329-35.
103. Savage S, Estacio RO, Jeffers B, Schrier RW. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. *Proc Assoc Am Physicians*. 1997 Mar;109(2):181-9.
104. Donner T, Muñoz M. Update on insulin therapy for type 2 diabetes. *J Clin Endocrinol Metab*. 2012 May;97(5):1405-13.
105. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes--causes, effects and coping strategies. *Diabetes Obes Metab*. 2007 Nov;9(6):799-812.
106. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007 Jun 14;356(24):2457-71.

107. Sobenin IA, Maksumova MA, Slavina ES, Balabolkin MI, Orekhov AN. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. *Atherosclerosis*. 1994 Feb;105(2):159-63.
108. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. *Gastroenterology*. 2009 Aug;137(2):482-8.
109. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. *Gastroenterology*. 2004 Oct;127(4):1044-50.
110. Perseghin G, Calori G, Lattuada G, et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. *Acta Diabetol*. 2012 Dec;49(6):421-8.
111. Available at: <http://edrv.endojournals.org/content/24/3/278.full>. Accessed April 18, 2013.
112. Ruskovska T, Bernlohr DA. Oxidative stress and protein carbonylation in adipose tissue - Implications for insulin resistance and diabetes mellitus. *J Proteomics*. 2013 Apr 11. [Epub ahead of print]
113. Andersen DK. Diabetes and cancer: placing the association in perspective. *Curr Opin Endocrinol Diabetes Obes*. 2013 Apr;20(2):81-6.
114. Aleksandrova K, Nimptsch K, Pischon T. Obesity and colorectal cancer. *Front Biosci (Elite Ed)*. 2013 Jan 1;5:61-77.
115. Gunter JH, Sarkar PL, Lubik AA, Nelson CC. New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. *Int J Cell Biol*. 2013;2013:834684.
116. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. *Cancer Sci*. 2013 Jan;104(1):9-14.
117. Aleksandrova K, Nimptsch K, Pischon T. Influence of Obesity and Related Metabolic Alterations on Colorectal Cancer Risk. *Curr Nutr Rep*. 2013 Mar;2(1):1-9.
118. Seim I, Lubik AA, Lehman ML, et al. Cloning of a novel insulin-regulated ghrelin transcript in prostate cancer. *J Mol Endocrinol*. 2013 Feb 15;50(2):179-91.
119. Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. *Endocr Relat Cancer*. 2012 Nov 9;19(6):785-92.
120. Berryhill GE, Gloviczki JM, Trott JF, et al. Diet-induced metabolic change induces estrogen-independent allometric mammary growth. *Proc Natl Acad Sci U S A*. 2012 Oct 2;109(40):16294-9.
121. Vidal AC, Lund PK, Hoyo C, et al. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. *BMC Cancer*. 2012 Sep 5;12:389.
122. Campagnoli C, Abbà C, Ambroggio S, Brucato T, Pasanisi P. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. *Gynecol Endocrinol*. 2013 Feb;29(2):119-24.

123. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. *Endocr Relat Cancer*. 2012 Nov 9;19(6):R225-41.
124. Cui Y, Andersen DK. Diabetes and pancreatic cancer. *Endocr Relat Cancer*. 2012 Sep 5;19(5):F9-F26.
125. Arcidiacono B, Iritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. *Exp Diabetes Res*. 2012;2012:789174.
126. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. *Jpn J Cancer Res*. 1989 Jan;80(1):51-8.
127. Available at: http://www.huffingtonpost.com/2013/03/06/alzheimers-health-united-states-america-threat_n_2820887.html. Accessed April 18, 2013.
128. Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. *Ann N Y Acad Sci*. 2000;924:170-83.
129. Chen JX, Yan SD. Amyloid-beta-induced mitochondrial dysfunction. *J Alzheimers Dis*. 2007 Sep;12(2):177-84.
130. Lustbader JW, Cirilli M, Lin C, et al. Aβ directly links Abeta to mitochondrial toxicity in Alzheimer's disease. *Science*. 2004 Apr 16;304(5669):448-52.
131. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. *J Neurosci*. 2009 Jul 15;29(28):9090-103.
132. Muller WE, Eckert A, Kurz C, Eckert GP, Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. *Mol Neurobiol*. 2010 Jun;41(2-3):159-71.
133. Moreira PI, Harris PL, Zhu X, et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. *J Alzheimers Dis*. 2007 Sep;12(2):195-206.
134. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. *Arch Neurol*. 2005 Oct;62(10):1539-44.
135. Available at: <http://www.hindawi.com/journals/tswj/2012/756357/>. Accessed April 18, 2013.
136. Jovanović Z. Mechanisms of neurodegeneration in Alzheimer's disease. *Med Pregl*. 2012 Jul-Aug;65(7-8):301-7.
137. Umegaki H. Neurodegeneration in diabetes mellitus. *Adv Exp Med Biol*. 2012;724:258-65.
138. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. *Drugs*. 2012 Jan 1;72(1):49-66.

139. Faivre E, Holscher C. Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. *Alzheimers Res Ther.* 2013 Apr 19;5(2):20.
140. Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A. Brain insulin dysregulation: Implication for neurological and neuropsychiatric disorders. *Mol Neurobiol.* 2013 Jan 20. [Epub ahead of print]
141. Bianchi C, Miccoli R, Trombetta MJ. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: The GENFIEV Study. *Clin Endocrinol Metab.* 2013 Mar 28. [Epub ahead of print]
142. Othman EM, Leyh A, Stopper H. Insulin mediated DNA damage in mammalian colon cells and human lymphocytes in vitro. *Mutat Res.* 2013 Mar 21. [Epub ahead of print]
143. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic fatty liver disease in nondiabetic adults. *Am J Med.* 2011 Jan;124(1):69-76.
144. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. *Diabetes.* 2002 Apr;51(4):1226-32.
145. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. *Am J Kidney Dis.* 2005 45(2):275-80.
146. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. *J Am Soc Nephrol.* 2005;16(7):2134-40.
147. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. *J Clin Endocrin Metab.* 2012;97(4):1268-76.
148. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. *Curr Opin Investig Drugs.* 2009 Oct;10(10):1049-60.
149. S Roriz-Filho J, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. *Biochim Biophys Acta.* 2009 May;1792(5):432-43.
150. Abdelmoneim SS, Hagen ME, Mendrick E, et al. Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography. *Heart Vessels.* 2012 Nov 23.
151. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. *Arterioscler Thromb Vasc Biol.* 2012 Aug;32(8):1754-9.
152. Sasaki M, Joh T, Koikeda S, et al. A novel strategy in production of oligosaccharides in digestive tract: prevention of postprandial hyperglycemia and hyperinsulinemia. *J Clin Biochem Nutr.* 2007 Nov;41(3):191-6.

153. Ao Z, Simsek S, Zhang G, Venkatachalam M, Reuhs BL, Hamaker BR. Starch with a slow digestion property produced by altering its chain length, branch density, and crystalline structure. *J Agric Food Chem*. 2007 May 30;55(11):4540-7.
154. Ota M, Okamoto T, Wakabayashi H. Action of transglucosidase from *Aspergillus niger* on maltoheptaose and [U-(13)C]maltose. *Carbohydr Res*. 2009 Mar 10;344(4):460-5.